Close Menu

marketing agreement

Under one deal, AstraNet will sell Norton's protein aggregation monitoring device in Europe, while under another, Advanced Scientific Technologies will sell PAM in the mid-Atlantic region.

Health Diagnostic Laboratory will offer the galectin-3 test to physicians along with its own cardiovascular tests.

IDT will produce the assays and market them through an online catalog directly to customers of Quanta.

The deal will make Ambry the preferred provider of genetic carrier screening for LABS and give LABS' customers access to Ambry's genetic screen for identifying carriers of severe and common childhood diseases.

The firms will co-develop a new tissue-based imaging and analysis solutions for protein biomarkers.

Seahorse Extracellular and Flux Analyzers provide a kinetic method of measuring mitochondrial respiration and glycolysis, the two major energy-producing pathways, in living cells in a microplate, the company said.

Shimadzu's LC and GC systems sold in the US will come with Phenomenex columns, under the terms of the deal.

The deal will take Novartis into the blood genotyping market.

LabCorp will be XDx's preferred third-party, non-hospital provider for phlebotomy and specimen processing for all XDx AlloMap molecular expression tests conducted in North America.

The agreement follows yesterday's announcement of a similar pact with Ion Torrent.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.